Australian journal of general practice · 2025
Pharmaceutical pitfalls in treating patients with advanced cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gurgenci Taylan, Chen Jones, Jull Benjamin, Stokes Claire, Eu Dominic, Good Phillip
Аннотация
BACKGROUND: This paper presents a collection of important topics that are not related to the other Focus papers in this AJGP issue on palliative care but are nevertheless important for clinical practice.
OBJECTIVE: This article reviews the safe use of fentanyl, the proper use of buprenorphine and oxycodone-naloxone, and the potential pitfalls of equianalgesic tables.
DISCUSSION: Sublingual and transdermal fentanyl are contraindicated in patients who are opioid-naïve. Opioid-naïve has a strict definition. Buprenorphine does not reduce the efficacy of other analgesics. Equianalgesic tables should not be followed blindly - they have many shortcomings, even if they are the best guidance we have. The benefit of combined oxycodone-naloxone products is modest in patients receiving palliative care in whom there is a higher risk of therapeutic failure and adverse effects. In summary, these are clinical topics that frequently arise when specialist input is sought but are not directly addressed in most clinical articles.
OBJECTIVE: This article reviews the safe use of fentanyl, the proper use of buprenorphine and oxycodone-naloxone, and the potential pitfalls of equianalgesic tables.
DISCUSSION: Sublingual and transdermal fentanyl are contraindicated in patients who are opioid-naïve. Opioid-naïve has a strict definition. Buprenorphine does not reduce the efficacy of other analgesics. Equianalgesic tables should not be followed blindly - they have many shortcomings, even if they are the best guidance we have. The benefit of combined oxycodone-naloxone products is modest in patients receiving palliative care in whom there is a higher risk of therapeutic failure and adverse effects. In summary, these are clinical topics that frequently arise when specialist input is sought but are not directly addressed in most clinical articles.